How did ENSC's revenue and expenses trend in Q4 2024?

Ensysce Biosciences (NASDAQ:ENSC) demonstrated significant improvements in revenue and profitability in Q4 2024, driven primarily by higher revenue and operational efficiencies. 1. **Revenue Growth**: Ensysce Biosciences reported a revenue of $3.42 million for Q4 2024, marking a substantial increase from the $2.98 million recorded in the same quarter of the previous year. This upward trend indicates a strong market demand for the company's products and services. 2. **Expense Management**: The company's net income for Q4 2024 was $661.8 thousand, a stark contrast to the $2.69 million net loss reported in the same quarter of the previous year. This significant improvement in net income suggests effective cost management and operational efficiencies. |code|Ticker|Name|Date|Business Composition|Revenue By Business|market_code| |---|---|---|---|---|---|---| |ENSC|ENSC.O|Ensysce Biosciences|20240101-2024|Opioid Use Disorder Grant|2123567|186| |ENSC|ENSC.O|Ensysce Biosciences|20240101-2024|Opioid Use Disorder Grant|2123567|186| |ENSC|ENSC.O|Ensysce Biosciences|20240101-2024|Opioid Use Disorder Grant|487519|186| |ENSC|ENSC.O|Ensysce Biosciences|20240101-2024|Opioid Use Disorder Grant|305722|186| |ENSC|ENSC.O|Ensysce Biosciences|20240101-2024|Opioid Use Disorder Grant|305722|186| |code|Ticker|Name|Date|Selling, General, and Administrative Expenses|R&D Expenses|Advertising and Marketing Expenses|market_code| |---|---|---|---|---|---|---|---| |ENSC|ENSC.O|Ensysce Biosciences|2024 Q1|1369782|778904||186| |ENSC|ENSC.O|Ensysce Biosciences|2024 Q2|1190010|947229||186| |ENSC|ENSC.O|Ensysce Biosciences|2024 Q3|1083433|1690674||186| |ENSC|ENSC.O|Ensysce Biosciences|2024 Q4|1077505|3802630||186| 3. **Profit Margin Improvement**: Ensysce Biosciences achieved a profit margin of 19% in Q4 2024, up from a net loss in the same quarter of the previous year. This improvement in profit margin reflects the company's focus on profitability and its ability to convert revenue into net income. 4. **EPS Improvement**: The company's earnings per share (EPS) for Q4 2024 was $0.067, a substantial increase from the $0.87 loss per share reported in the same quarter of the previous year. This indicates not only improved profitability but also enhanced shareholder value. 5. **Operational Positive Trends**: Ensysce Biosciences has regained compliance with Nasdaq's minimum bid price requirement, reflecting stability and growth in its stock value. Additionally, the company's supply chain has been secured for a critical component of its overdose protection drug product, ensuring continued development and commercialization of this innovative solution. In conclusion, Ensysce Biosciences experienced a notable increase in revenue and a significant improvement in net income in Q4 2024, accompanied by enhanced profit margins and EPS. These positive trends underscore the company's successful operational strategies and its potential for continued growth and profitability.